A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.E. | - |
dc.contributor.author | Yoon, D.H. | - |
dc.contributor.author | Jang, G. | - |
dc.contributor.author | Lee, D.H. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Park, C.-S. | - |
dc.contributor.author | Huh, J. | - |
dc.contributor.author | Kim, W.S. | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Lee, S.I. | - |
dc.contributor.author | Suh, C. | - |
dc.date.available | 2020-02-29T09:43:46Z | - |
dc.date.created | 2020-02-11 | - |
dc.date.issued | 2012-03 | - |
dc.identifier.issn | 1738-7949 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17437 | - |
dc.description.abstract | Background Bortezomib targets molecular dysregulation of nuclear factor-κB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of bortezomib treatment with dose-dense cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 2 weeks(CHOP-14). Methods Untreated DLBCL patients were enrolled. A phase I dose-escalation study with 1.0, 1.3, and 1.6 mg/m 2 bortezomib administration on day 1 and 4 in addition to the CHOP-14regimen was performed to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT). Lenograstim 5 μg/kg/d was administered on day 4-13. The bortezomib dose from the phase I study was used in the phase II study. Results Nine and 37 patients were enrolled in the phase I and phase II studies, respectively. The analysis of the phase II results (40 patients) included data of the 3 patients in the last MTD dose cohort of the phase I trial. During the phase I trial, no DLT was observed at any bortezomib dose; therefore, the recommended dose was 1.6 mg/m 2. In phase II, the overall response rate was 95% (complete response: 80%; partial response: 15%). Nine out of the 40 patients showed grade 3 sensory neuropathy, and 22 required at least 1 dose reduction. Three patients could not complete the intended 6 cycles of treatment because of severe neuropathy. Conclusion Bortezomib plus CHOP-14 was highly effective for the treatment of untreated DLBCL patients, but in many cases, dose or schedule modification was required to reduce neurotoxicity. © 2012 Korean Society of Hematology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한혈액학회 | - |
dc.relation.isPartOf | Korean Journal of Hematology | - |
dc.title | A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.5045/kjh.2012.47.1.53 | - |
dc.identifier.bibliographicCitation | Korean Journal of Hematology, v.47, no.1, pp.53 - 59 | - |
dc.identifier.kciid | ART001645669 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84866927154 | - |
dc.citation.endPage | 59 | - |
dc.citation.startPage | 53 | - |
dc.citation.title | Korean Journal of Hematology | - |
dc.citation.volume | 47 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Park, J. | - |
dc.contributor.affiliatedAuthor | Lee, J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Bortezomib | - |
dc.subject.keywordAuthor | Chop-14 | - |
dc.subject.keywordAuthor | Diffuse large b-cell lymphoma | - |
dc.subject.keywordPlus | bortezomib | - |
dc.subject.keywordPlus | cyclophosphamide | - |
dc.subject.keywordPlus | doxorubicin | - |
dc.subject.keywordPlus | prednisone | - |
dc.subject.keywordPlus | recombinant granulocyte colony stimulating factor | - |
dc.subject.keywordPlus | vincristine sulfate | - |
dc.subject.keywordPlus | abdominal pain | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | advanced cancer | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | anemia | - |
dc.subject.keywordPlus | anorexia | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer staging | - |
dc.subject.keywordPlus | clinical evaluation | - |
dc.subject.keywordPlus | constipation | - |
dc.subject.keywordPlus | diarrhea | - |
dc.subject.keywordPlus | drug dose increase | - |
dc.subject.keywordPlus | drug dose reduction | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug megadose | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | fatigue | - |
dc.subject.keywordPlus | febrile neutropenia | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | fever | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hyperglycemia | - |
dc.subject.keywordPlus | hypoalbuminemia | - |
dc.subject.keywordPlus | hypocalcemia | - |
dc.subject.keywordPlus | hypokalemia | - |
dc.subject.keywordPlus | large cell lymphoma | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | maximum tolerated dose | - |
dc.subject.keywordPlus | motor neuropathy | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | neutropenia | - |
dc.subject.keywordPlus | phase 1 clinical trial | - |
dc.subject.keywordPlus | phase 2 clinical trial | - |
dc.subject.keywordPlus | sensory neuropathy | - |
dc.subject.keywordPlus | thrombocytopenia | - |
dc.subject.keywordPlus | vomiting | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.